In vivo real-time tracking of “color-coded” supercharged Mesenchymal Stem Cells and T cells in allograft rejection

体内实时跟踪同种异体移植排斥反应中的“颜色编码”增压间充质干细胞和 T 细胞

• 批准号: nhmrc : 1143655
• 金额: $ 27.82万
• 依托单位: The University of Adelaide
• 依托单位国家: 澳大利亚
• 项目类别: Early Career Fellowships
• 财政年份: 2018
• 资助国家: 澳大利亚
• 起止时间: 2018-01-01 至 2022-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/vivo-real-time-allograft-rejection/1320004
• 关键词: vivo; real; time; tracking; color

Growing specialized adult stem cells (MSC) in the presence of a unique immune signaling protein (IL-17) has generated a “supercharged” stem cell with superior abilities to dampen immune responses in cell and organ transplant patients. The use of these MSC in transplant patients may significantly reduce the dose of anti-rejection drugs required to prevent cell and organ rejection. By minimizing the dose of drugs, we aim to eliminate the risk of developing infections and cancer in these patients.

在存在独特的免疫信号传导蛋白（IL-17）的情况下培养特化的成体干细胞（MSC）已经产生了一种“增压”干细胞，其具有抑制细胞和器官移植患者的免疫反应的上级能力。在移植患者中使用这些MSC可以显着减少预防细胞和器官排斥所需的抗排斥药物的剂量。通过最大限度地减少药物剂量，我们的目标是消除这些患者发生感染和癌症的风险。